Biosimulation Market Size, Share, Trends, Growth 2032

Global Biosimulation Market Overview:

The global biosimulation market size was worth around USD 2.67 billion in 2023 and is predicted to grow to around USD 10.20 billion by 2032 with a compound annual growth rate (CAGR) of roughly 16.05% between 2024 and 2032.

Request Free Sample

The report covers a forecast and an analysis of the biosimulation market on a global and regional level. The study provides historical data for 2018 and 2022 along with a forecast from 2024 to 2032 based on revenue (USD Billion). The study includes drivers and restraints of the biosimulation market along with their impact on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the biosimulation market on a global level.

Biosimulation Market: Growth Drivers

Biosimulation is a biomedical research approach for patient treatment, where computer modeling is utilized along with clinical and experimental trials. It is referred to as a tool used for prediction of the outcomes of existing trials associated with innovation and new drug development. The extensive need for advanced-generation therapeutics due to the rise in the occurrences of chronic diseases, such as diabetes and cancer, will fuel the growth of the global biosimulation market over the forecast timeline.

The development of improved technology, adoption of advanced software, and rising expenditure on healthcare will prominently boost the biosimulation market growth globally over the forecast time period. High clinical urgency to develop and discover advanced and high potency drugs are also estimated to play a crucial role in the growth of the global biosimulation market in the future. The other influencing factors, such as the rising healthcare expenditure and increasing adoption of advanced technology and software, will also support the global biosimulation market growth over the estimated time period.

Request Free Sample

In order to give the users of this report a comprehensive view of the biosimulation market, we have included a competitive landscape and an analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all the segments are benchmarked based on their market size, growth rate, and general attractiveness.

The report provides company market share analysis to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new technology launch, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the market on a global and regional basis. Moreover, the study covers price trend analysis and product portfolio of various companies according to regions.

Biosimulation Market : Report Scope

Biosimulation Market: Segmentation

The study provides a decisive view of the biosimulation market based on product, application, end-user, and region.

Based on Product, the market is segmented into services and software. The services segment is further classified into contract services and in-house services. The services segment is expected to register the highest growth rate over the estimated time period, owing to the aggregate complexities and multi-layered drug development systems.

By Application, the market includes drug discovery, drug development, and others. The drug discovery segment is anticipated to grow at a noteworthy rate, owing to the increasing adoption of biosimulation in pharmacogenetics and pharmacogenomics over the forecast timeline.

By End-User, the market is segmented into pharmaceutical and biotechnology companies, contract research organizations, regulatory authorities, and academic research institutions. The contract research organizations segment is estimated to register the highest growth rate in the future.

Biosimulation Market: Regional Analysis

The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa with its further divided into major countries including the U.S., Germany, France, UK, China, Japan, India, and Brazil. 

North America is projected to dominate the global biosimulation market throughout the forecast time period, owing to a large number of clinical trials and drug development practices, increasing growth of pharmaceutical and biotechnology companies, and growing adoption of personalized medicines. Europe held the second largest share of the global biosimulation market in 2018. The Asia Pacific biosimulation market is expected to grow rapidly over the forecast timeline, owing to the increasing preference for contract research organizations, developing healthcare infrastructure, and rising expenditure in the healthcare IT sector. Latin America and the Middle East and Africa are expected to experience moderate market growth in the years to come.

Biosimulation Market: Competitive Analysis

The global biosimulation market is dominated by players like:

• Dassault Systèmes SE
• Certara USA, Inc
• Chemical Computing Group
• Physiomics
• In Silico Biosciences
• INOSIM Software
• Advanced Chemistry Development, Inc
• Schrodinger, Inc
• Genedata AG
• Rhenovia Pharma Ltd

This report segments the global biosimulation market as follows:

Global Biosimulation Market: Product Analysis

• Software
• Services 
  • In-House Services
  • Contract Services

Global Biosimulation Market: Application Analysis

• Drug Development
• Drug Discovery
• Others

Global Biosimulation Market: End-User Analysis

• Pharmaceutical and Biotechnology Companies
• Contract Research Organizations
• Regulatory Authorities
• Academic Research Institutions

Global Biosimulation Market: Regional Analysis

• North America
  • The U.S.
• Europe
  • UK
  • France
  • Germany
• Asia Pacific
  • China
  • Japan
  • India
• Latin America
  • Brazil
• Middle East and Africa